BIOCHEMICS, INC. TO PRESENT AT SECOND ANNUAL BOSTON BIOTECH R&D CONFERENCE
BOSTON, MA [October 01, 2009] – BioChemics today announced that John J. Masiz, Esq. President and CEO will present at the 2009 Boston Biotech R&D Conference, at 4:00 on October 27, 2009 at Harvard Medical School in Boston, Mass. This conference will bring luminaries from top academic institutions that have been instrumental in establishing the strong Boston biotech community together with executives from several of the area’s most promising emerging biopharmaceutical companies, as well as leaders from the venture capital community and equity markets.
John Masiz will lead a session entitled “Transdermal Drug Delivery Through Biophysical and Biochemical Modulation”. During the presentation, John Masiz will focus on the advances that BioChemics has made in understanding sub structures (both biochemical and biophysical) in the skin and the Companies’ advances in opening those barriers to enable efficient transdermal deliver for drugs that have never before been delivered through the skin.
“We are very pleased to be participating in the second annual Boston Biotech R&D conference,” said Mr. Masiz. “The conference is an excellent forum to share information with other leading biotech and pharmaceutical companies in our community in order to foster both co-ordination and cooperation to hopefully accelerate drug development and drive novel products to market.”
ABOUT BIOCHEMICS, INC.
BioChemics is a specialty pharmaceutical company that has developed a novel, transdermal drug delivery system called VALE® (Vaso-active Lipid Encapsulated) that for the first time may allow almost any drug to be efficiently delivered through the skin. BioChemics is working to build a deep pipeline of drug products focused on multi-billion dollar markets that are currently underserved by current therapies. The company’s lead clinical programs are focused on osteoarthritis and neuropathic pain management. In addition, the Company has developed two other drug delivery technologies: PENtoCORE® (for topical delivery) and mNET™ (MicroNeedle Enabling Technology) which allow both topical as well as systemic delivery for larger molecules (e.g., proteins and peptides).
ABOUT THE BOSTON BIOTECH R&D